Anonymous client report · 74 members · 6 months

See the results of 6 months of Embla

Wondering what results your organization can expect with Embla? Get the 6-month performance report we sent to one of our US employer clients.

View the report instantly and get it send to your inbox.

2026

Client

Performance
report

Data from 6 months of Embla

Comprehensive overview of clinic performance — member engagement, weight progression, and cost savings achieved through the Embla platform.

74Members

6 mo.Period

$668kSavings

98.6%Engaged

98.6%Member engagement

$668kEst. savings

By the numbers

30%

Better weight loss outcomes vs. industry standard care over 6 months

98.6%

Member engagement at 60 days Industry standard: 65%

66%

Fewer side effects vs. real-world GLP-1 studies

What's in the report

Six months of data. No projections. No rounding up.

Adoption rates and engagement breakdown benchmarked against industry averages across 14, 30, and 60 day windows.

Month-by-month weight loss data vs. real-world GLP-1 studies. 30% better outcomes than standard care.

Average dosage per member by drug type — Tirzepatide, Semaglutide, Ozempic — vs. industry standard. Members used 50–73% less.

Savings by BMI class with full methodology. GLP-1 medication savings calculated separately. $668k total estimated savings.

Rate and type reported — 66% fewer than real-world GLP-1 studies. Low-dose approach reduces adverse events significantly.

121 healthy life years and 101.5 life expectancy years gained across the 74-member population over 6 months.

See the full data for yourself.

We'll send the report and follow up with a short note from our team.

You'll get added to our mailing list but can unsubscribe at any time.